Zuranolone: Novel, Rapid-Acting Antidepressant Awaits FDA Approval
A New Drug Application for zuranolone awaits FDA approval for the treatment of major depressive disorder (MDD) and postpartum depression (PPD).
Prenatal Exposure to Topiramate (Topamax): Impact on Neurodevelopmental Outcomes
Data from a Nordic register-based study observed a significant increase in risk for autism spectrum disorder and intellectual disability in children with prenatal exposure to topiramate.
Best Wishes for the Holiday Season from the MGH Center for Women’s Mental Health
Best wishes for the holiday season from the Center for Women's Mental Health.
Buprenorphine or Methadone: Which One is Better for the Treatment of Opioid Use Disorder in Pregnancy?
Treatment with buprenorphine versus methadone during pregnancy is associated with lower risk of preterm birth, low birth weight, small size for gestational age, and NAS.
Increased Risk of Preterm Birth in Veterans with PTSD
Largest studies to date demonstrate statistically significant risk of preterm birth among women with active PTSD.
Weekly Roundup for DECEMBER 9, 2022: Recent Publications in Women’s Mental Health
Every week we review the most recent publications in women’s mental health.
Essential Reads: Prenatal Exposure to Benzodiazepines and Neurodevelopmental Outcomes
The largest study to date observes no increase in risk of autism or ADHD in children with prenatal exposure to benzodiazepines.
Essential Reads: Peer Support Interventions for Perinatal Depression
Peer support interventions can reduce the incidence of postpartum depression and the severity of depressive symptoms.
What You May Have Missed Last Week – December 12, 2021
Cannabis use in preganat and menopausal women, COVID and worse pregnancy outcomes but some antivirals appear to be safe, new fertility trachers.
Essential Reads: Why Non-Randomized Studies Fall Short When Assessing Reproductive Safety
All of our information on the reproductive safety of medications comes from non-randomized studies. However, many of these studies fail to take into consideration other factors associated with maternal psychiatric illness which may also affect outcomes.